EXPRESSIONS OF SRAGE AND MMP-9 IN THE SERUM OF PATIENTS WITH COPD COMPLICATED WITH DIABETES MELLITUS AND CLINICAL SIGNIFICANCE

Dong-Fang Zhao¹, Ye Zhang¹, Yin-Peng Li¹, Fang Shi¹, Jun-Xia Liu¹, Yan Wang¹, Jia-Qi Liu², Chang-Lan Gao¹, Meng-Miao Pei¹, Pei-Xiu Li³, Zheng Liu^{1, *}

¹Department of Respiration, the Petroleum Clinical Medical College of Hebei Medical University, Hebei 065000, China - ²Faculty of Science-Medical Science Major, University of Western Ontario, London, ON N6A 3K7, Canada - ³Department of Radiology, the Petroleum Clinical Medical College of Hebei Medical University, Hebei 065000, China

Objective: The aims of this study were to investigate the expressions and clinical features of advanced soluble glycation end products (sRAGE) and matrix metalloproteinases (MMPs)-9 in the serum of patients with chronic obstructive pulmonary disease (COPD) complicated with diabetes mellitus (DM).

Materials and methods: Seventy-six patients with COPD admited from January 2017 to November 2017 were divided into the observation group (O, patients with COPD-DM) and the control group (C, patients with COPD while non-DM). The patients were examined the pulmonary function, CAT score, and chest high-resolution computed tomography (HRCT) due to acute episodes (which is divided into the emphysema phenotype (Group OE) and airway inflammation phenotype (Group OA). Fasting blood was taken for routine examination and determination of sRAGE and MMP-9 levels.

Results: The expression level of sRAGE in Group O was 1414.64 pg/mL higher than that group C (937.98 pg/mL) (P<0.05). The sRAGE level in Group OA was 1868.63pg/mL higher than Group OE 1291.11 pg/mL (Z=-2.51, P=0.012). The sRAGE level in Group OA was was 1688.63pg/mL higher than Group C 1176.47 pg/mL (Z=-3.46, P=0.001); The serum sRAGE and MMP-9 levels were significantly correlated with the neutrophil percentage in group OA (r=0.73, 0.47, P=0.017, 0.014).

Conclusions: sRAGE and MMP-9 are involved in the pathogenesis of COPD combined with diabetes and have certain clinical value in evaluating clinical subgroup.